NCT04332653 2026-03-09NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsNeoImmuneTechPhase 1/2 Completed215 enrolled 30 charts
NCT03901573 2025-10-22High-Risk Skin Cancers With Atezolizumab Plus NT-I7NeoImmuneTechPhase 1/2 Terminated31 enrolled 12 charts